


Price	114.4p
Market Cap	£330.2m
Shares in Issue	288.7m
12m Trading Range	106.5p – 160.0p
Free Float	77.9%
Next Event	H1 trading update – July

Price performance (p)



Source: Bloomberg

Financial forecasts

Yr end Dec (\$'m)	2022A	2023E	2024E	2025E
Revenue	728.2	825.5	868.9	921.2
YoY growth (%)	77.4	13.4	5.3	6.0
Gross profit	177.7	189.7	199.2	210.5
Adj. EBITDA	86.0	91.8	97.3	104.5
Adj. EBITDA/ Net revenue (%)	48.4	48.4	48.8	49.6
Net cash (debt)	(56.8)	(37.1)	16.4	70.9
EV/EBITDA (x)	5.4	4.9	4.1	3.3
EV/EBIT (x)	5.6	5.0	4.2	3.4
P/E (x)	7.1	6.8	6.4	5.9
FCFF yield (%)	13.4	15.3	18.8	22.6

Source: Audited accounts and Zeus estimates

Analysts

Bob Liao, CFA
+44 (0) 7791 960 487
bob.liao@zeuscapital.co.uk

Carl Smith, CFA
+44 (0) 7707 270 997
carl.smith@zeuscapital.co.uk

Zeus Contacts

Emma Ayton	+44 20 3829 5622
Victoria Ayton	+44 20 3829 5603
Tim Dainton	+44 20 3829 5637
Simon Johnson	+44 20 3829 5631
Dominic King	+44 20 3829 5607
Gregor Paterson	+44 131 370 3705
John Peat	+44 20 3829 5639
Ben Robertson	+44 20 3829 5625
Nick Searle	+44 20 3829 5633
Rupert Woollfenden	+44 20 3829 5623

Email: firstname.surname@zeuscapital.co.uk

CentralNic

CNIC LN - Technology

Broadening growth drivers

Q1 revenue, Adjusted EBITDA, cash and net debt were all in line with the Q1 trading update in April and the company outlook indicates this is continuing into Q2. We expect growth in the remainder of the year to be boosted by its new partnership with Bing, new margin enhancing products and geographic expansion. We also see margins expanding as revenues continue growing whilst expenses remain steady. We upgrade our revenue forecasts based on a strong Q1 but conservatively keep our Adjusted EBITDA estimates unchanged. We estimate Adjusted EBITDA in the remaining three quarters of the year needs to grow only 4% YoY to meet our 2023 estimate. Based on these conservative forecasts, shares trade at only 5x 2023 EBITDA and 7x P/E. As a sign of confidence in share price value and earnings growth, CentralNic has announced a \$4m second share buyback programme.

Q1 results: Q1 revenue was \$194.9m, up ~46% organically over the last twelve months (LTM)(2022: ~60%). The Online Marketing division grew ~60% organically (2022: ~83%) and the Online Presence division accelerated organic growth to c. 10% over the LTM (2022: 4%). Adjusted EBITDA grew 15% yoy whilst Adjusted EBITDA/ Gross profit was steady yoy at c. 46.5%. Free cash flow to equity was \$12.4m, equal to 12% FCFE yield on an annualised basis. \$4.0m of FCFE was used to repurchase shares and make acquisition related payments of \$1.9m. Largely due to these key movements, net debt including hedging liabilities fell to \$49.3m from \$56.6m at year end 2022.

New partners, products and geographies to boost growth: First, CentralNic has partnered with Microsoft to provide CentralNic with access to Bing's portfolio of advertisers, as announced previously. We see potential long-term upside as the company builds another high growth, traffic conversion business around Bing and complements its existing business with Google. Second, the Online Marketing division plans to introduce products to help it source traffic directly, allowing the company to reduce gross costs and expand gross margins. Third, the Online Marketing division has recently expanded its product comparison lead generation business to France, the second largest European market for Amazon, its key partner.

Strong operating leverage: CentralNic's expense base is stable, which should allow continued revenue growth to expand margins. Adjusted expenses were \$24.5m in Q1 2023, steady compared to \$24.4m in Q4 2022. Whilst we expect Adjusted expenses to remain steady for the remainder of the year, we expect average revenue to grow by 8% over the last three quarters. As a result, we forecast Adjusted EBITDA/ Gross profit margin to average 49.0% in the last three quarters of 2023, up from 46.5% in Q1 2023.

Revenue upgrades: Q1 revenue is tracking well ahead of our original full year forecast. Annualised Q1 revenue is \$780m, greater than our original full year forecast of \$772m and revenues are likely to continue growing over the remaining quarters of the year. Therefore, we upgrade our 2023 revenue estimates by 7%. We assume pro forma gross margins for Online Marketing (20%) will be unchanged from Q1 2023, balanced between the positive effects of increased direct media buying and the potential negative effects of expansion into new verticals. We also assume Online Presence gross margins (33.5%) and Adjusted expenses (\$24.5m per quarter) remain steady over the remainder of the year. The effect of higher revenues is offset by lower gross margins and higher expenses, leading us to leave our Adjusted EBITDA forecasts unchanged for 2023 and beyond.

Forecasts revisions

Exhibit 1: Changes to estimates

Yr end Dec (\$'m)	2023E new	2023E old	% diff	2024E new	2024E old	% diff	2025E new	2025E old	% diff
Revenue	825.5	771.8	7.0	868.9	818.4	6.2	921.2	868.0	6.1
Net revenue/ Gross profit	189.7	187.6	1.1	199.2	196.9	1.2	210.5	208.1	1.2
Adj EBITDA	91.8	91.8	-	97.3	97.3	-	104.5	104.5	-
EBITDA/ Net revenue margin (%)	48.4	48.9	(1.1)	48.8	49.4	(1.2)	49.6	50.2	(1.1)
Adj. PBT	79.2	79.2	-	84.7	84.7	-	91.9	91.9	-
Adj. PAT	57.4	57.4	-	61.4	61.4	-	66.6	66.6	-
Adjusted EPS - Basic (cents)	20.8	20.7	0.6	22.4	22.1	1.2	24.3	24.0	1.2
Net debt/(cash) including FX hedges	37.1	26.7	38.9	(16.4)	(26.8)	(38.6)	(71.0)	(81.2)	(12.6)

Source: Company reports and Zeus estimates

In addition to revenue and Adjusted EBITDA revisions discussed on the front page, we also update our cash flow and net debt forecasts for the announced £4m share buyback (c. \$5m) and we add employee benefit trust (EBT) purchase of 3.6m shares (c. \$5.4m). Therefore, we increase our net debt estimate to \$37.1m from \$26.7m.

We conservatively estimate the impact of the buyback on weighted average share count by assuming a 120p average purchase price. As a result, the buyback increases adjusted EPS forecasts by 0.6% in FY23 and 1.2% in FY24 and FY25. We have also slightly decreased the cash outflow relating to deferred considerations to \$18.8m from \$19.0m. On 8 May 2023, the first deferred consideration payment for the acquisition of VGL was settled in cash for €12.4m (\$13.6m) as a result of the above expectation performance in 2022. Along with \$3.7m expected deferred consideration payment for Aporia, the total deferred consideration payment is now expected to be \$18.8m. The net effect of our changes is a c. \$10m increase in net debt in FY23 which flows through to later years.

Segmental details

Resilient Online Marketing growth: Pro forma growth in Q1 2023 remains resiliently in the double digits, slowing from triple digit growth due to a slowing macroeconomy. Pro forma yoy gross revenue growth was 17% in Q1 2023, compared to 50% in Q4 2022 and between 88% and 112% over the first three quarters of 2022. Pro forma gross margin was 20.4%, compared to 22.5% in Q4 2022. We expect gross margin to stabilise in a balance between margin enhancing new initiatives and expansion into lower margin verticals. The company expects new product releases to increase direct purchases of traffic, thereby reducing payments to media buyers. At the same time, CentralNic expects to expand traffic generation and conversion into new product categories that may be less profitable.

Overall, Q1 2023 pro forma gross profit was down 4%, compared to 22% growth in Q4 2022 and between 57% and 63% growth in the first three quarters of 2022. We expect new products such as traffic conversion for Bing and geographic expansion of CNIC's product comparison business to support higher growth in the remaining quarters of 2023. We conservatively forecast 13% pro forma revenue growth and 20.3% gross margins, resulting in 7% gross profit yoy growth in the remaining three quarters of 2023.

Acceleration in Online Presence: Growth accelerated whilst margins remain steady. Pro forma yoy gross revenue growth was 12% in Q1 2023 compared to 2% average quarterly growth in the four quarters of 2022. Pro forma gross margin was 33.6%, essentially unchanged from 33.7% in Q4 2022. We expect Online Presence to deliver reliable revenue and gross margins, leading to 4% growth in gross profit in the remaining three quarters of 2023.

Forecasts

Exhibit 2: Income statement

Year to December (\$m)	2021A	2022A	2023E	2024E	2025E
Online Presence	149.3	153.5	167.6	172.7	177.8
Online Marketing	261.3	574.7	657.8	696.3	743.4
Turnover:	410.5	728.2	825.5	868.9	921.2
Online Presence	53.3	52.6	56.2	57.9	59.6
Online Marketing	65.2	125.1	133.5	141.3	150.9
Gross Profit	118.5	177.7	189.7	199.2	210.5
SG&A	(72.2)	(91.7)	(97.9)	(101.9)	(106.0)
Adj. EBITDA	46.3	86.0	91.8	97.3	104.5
<i>Adj. EBITDA margin (Net revenue) (%)</i>	39.0	48.4	48.4	48.8	49.6
Depreciation	(3.5)	(3.0)	(2.8)	(2.8)	(2.8)
Adj. EBIT	42.7	83.0	89.0	94.5	101.7
Zeus Adj Interest	(10.9)	(13.0)	(9.8)	(9.8)	(9.8)
Zeus Adj PBT	31.8	70.0	79.2	84.7	91.9
Tax	(5.1)	(16.9)	(21.8)	(23.3)	(25.3)
Zeus Adj PAT	26.7	53.1	57.4	61.4	66.6
Reconciliation to reported numbers:					
Zeus Adj PBT	31.8	70.0	79.2	84.7	91.9
Share based payments	(5.0)	(5.7)	(5.7)	(5.7)	(5.7)
Amortisation	(18.3)	(36.4)	(36.4)	(36.4)	(36.4)
Share of associate income/ FX	1.6	(4.8)	-	-	-
Exceptional finance (costs)/income	0.1	(0.1)	-	-	-
Exceptional costs/income	(8.7)	(8.2)	(0.6)	-	-
Reported PBT	1.6	14.8	36.5	42.6	49.8
Tax	(5.1)	(16.9)	(21.8)	(23.3)	(25.3)
Reported PAT	(3.5)	(2.1)	14.7	19.3	24.5
Shares (Weighted) (excludes EBT shares)	227.4	265.6	275.6	273.9	273.9
Shares (Diluted) (excludes EBT shares)	234.2	268.2	278.2	278.2	278.2
Zeus Adj. EPS basic (cents)	11.8	20.0	20.8	22.4	24.3
Zeus Adj. EPS dil (cents)	11.4	19.8	20.6	22.1	24.0

Source: Company reports and Zeus estimates

Exhibit 3: Balance sheet

Year to Dec (\$m)	2021A	2022A	2023E	2024E	2025E
PP&E	8.6	7.4	5.6	3.9	2.2
Intangible assets	254.2	347.9	313.5	279.1	244.7
Deferred receivables	0.4	0.3	0.3	0.3	0.3
Investments	0.1	-	-	-	-
Deferred tax assets	8.6	9.5	9.5	9.5	9.5
Non-current assets	271.8	365.1	328.9	292.8	256.7
Trade and other receivables	71.4	98.2	113.1	119.0	126.2
Inventories	0.9	0.6	0.6	0.6	0.6
Cash & cash equivalents	56.1	94.8	114.4	167.9	222.5
Current assets	128.4	193.7	228.1	287.6	349.3
Total Assets	400.2	558.7	557.0	580.4	606.1
Liabilities					
Trade and other payables	(117.0)	(190.3)	(198.8)	(204.5)	(207.5)
Taxation payable	-	-	(3.7)	(4.8)	(6.3)
Lease liabilities	(1.8)	(3.8)	(1.6)	0.6	2.7
Derivative financial instruments	(6.4)	(0.1)	(0.1)	(0.1)	(0.1)
Borrowings	(11.9)	(5.3)	(5.3)	(5.3)	(5.3)
Current liabilities	(137.1)	(199.6)	(209.5)	(214.1)	(216.5)
Other payables	(4.4)	(13.9)	(0.2)	(0.2)	(0.2)
Lease liabilities	(5.1)	(1.9)	(1.9)	(1.9)	(1.9)
Deferred tax liabilities	(20.3)	(30.2)	(30.2)	(30.2)	(30.2)
Borrowings	-	(0.2)	(0.2)	(0.2)	(0.2)
Derivative financial instruments	(119.3)	(145.9)	(145.9)	(145.9)	(145.9)
Long term liabilities	(149.1)	(192.0)	(178.3)	(178.3)	(178.3)
Total Liabilities	(286.2)	(391.6)	(387.8)	(392.5)	(394.8)
Net assets	114.0	167.1	169.2	187.9	211.2
Equity					
Share capital	0.3	0.3	0.3	0.3	0.3
Share premium	39.8	98.3	98.3	98.3	98.3
Merger relief reserve	5.3	5.3	5.3	5.3	5.3
Share based payments reserve	19.5	24.1	15.0	20.7	26.4
Cash flow hedging reserve	(6.4)	(0.2)	(0.2)	(0.2)	(0.2)
FX reserves	2.9	(10.8)	(10.8)	(10.8)	(10.8)
Retained earnings	52.5	50.0	61.1	74.2	91.8
Total Equity	114.0	167.1	169.2	187.9	211.2

Source: Company reports and Zeus estimates

Exhibit 4: Cash flow statement

Year to December (\$m)	2021A	2022E	2023E	2024E	2025E
Cash flow from operating activities					
Profit /(Loss) before taxation	1.6	14.8	36.5	42.6	49.8
Adjustments for:					
Depreciation of property, plant and equipment	3.5	3.0	2.8	2.8	2.8
Amortisation of intangible assets	18.3	36.4	36.4	36.4	36.4
Share of associate income	-	-	-	-	-
Gain on sale of associate	-	-	-	-	-
Finance cost (net)	10.8	18.7	9.8	9.8	9.8
Share-based payments	5.0	5.7	5.7	5.7	5.7
Decrease in trade and other receivables	(20.8)	(9.9)	(14.8)	(6.0)	(7.2)
Increase in trade and other payables and accruals	24.6	16.9	13.5	8.2	6.5
Decrease in inventories	0.3	0.2	-	-	-
Cash flow from operations	43.3	85.9	89.9	99.5	103.9
Income tax paid	(2.2)	(8.4)	(18.1)	(22.2)	(23.8)
Net cash flow generated from operating activities	41.0	77.5	71.8	77.3	80.1
Cash flow used in investing activities					
Purchase of property, plant and equipment	(0.7)	(1.3)	(1.0)	(1.1)	(1.2)
Purchase of intangible assets, net of cash acquired	(4.1)	(13.5)	(2.0)	(2.0)	(2.0)
Payment of deferred consideration	(1.7)	(2.7)	(18.8)	(2.5)	(3.5)
Proceeds from disposal of investment in associate	-	0.2	-	-	-
Acquisition of subsidiaries, net of cash acquired	(18.3)	(73.3)	-	-	-
Net cash flow used in investing activities	(24.9)	(90.6)	(21.8)	(5.6)	(6.7)
Cash flow used in financing activities					
Proceeds from borrowings and repayments	25.7	38.1	-	-	-
Settlement of forward foreign exchange contracts	-	(25.5)	-	-	-
Accrued interest on bond tap	-	0.4	-	-	-
Bond arrangement fees	(1.0)	(4.2)	-	-	-
Proceeds from issuance of ordinary shares (net)	-	58.6	-	-	-
Repurchase of ordinary shares	-	(0.4)	(14.8)	-	-
Payment of finance leases	(2.0)	(2.2)	(2.2)	(2.2)	(2.2)
Dividends paid	-	-	(3.6)	(6.2)	(6.9)
Interest paid	(8.7)	(7.8)	(9.8)	(9.8)	(9.8)
Net cash flow generated from financing activities	14.0	57.0	(30.3)	(18.2)	(18.9)
Net increase in cash and cash equivalents	30.2	43.9	19.6	53.6	54.5
Cash and cash equivalents at beginning of the year	28.7	56.1	94.8	114.4	167.9
Exchange differences on cash and cash equivalents	(2.7)	(5.3)	-	-	-
Cash and cash equivalents at end of the year	56.1	94.8	114.4	167.9	222.5

Source: Company reports and Zeus estimates

Disclaimer

This document is issued by Zeus Capital Limited ("Zeus") (Incorporated in England & Wales No. 4417845), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority ("FCA") for designated investment business, (Reg No. 224621) and is a member firm of the London Stock Exchange.

Bob Liao, CFA & Carl Smith, CFA are the authors of this Investment Research. **Bob Liao, CFA & Carl Smith, CFA** are Investment Research Analysts and have been employed by Zeus to produce this research. There is no planned update to this research recommendation. The previous recommendation for CentralNic was **Positive** published **24/04/2023**.

Zeus is contractually engaged and paid by to produce research on an ongoing basis and as such, this research constitutes a minor non-monetary benefit. This research is made available at the time that it is first published to all professional clients and eligible counterparties via numerous research aggregators.

Unless otherwise stated any share prices used in this document are taken after market close on the business day prior to the date of publication. The date of completion and first dissemination of this research recommendation are the same and are as per the date-time displayed at the top of the document, unless otherwise stated. If the document references views of analysts other than the author named above then please refer to the price chart or rating history table for the date/time of completion and first dissemination with respect to that view.

This document is for information purposes only and neither the information contained, nor the opinions expressed, within this document constitute or are to be construed as an offer or a solicitation of an offer to buy or sell the securities or other instruments mentioned in it. It or any part of it does not form the basis of and should not be relied upon in connection with any contract. Subject to the nature and contents of the document, the investments described herein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal the amount invested. Certain investments contained in the document may have tax implications for private customers whereby levels and basis of taxation may be subject to change. Zeus does not provide tax advice and investors should seek advice from a tax adviser.

Zeus uses reasonable efforts to obtain information from sources which it believes to be reliable but the contents of this document have been prepared without any substantive analysis being undertaken into the companies concerned or their securities and it has not been independently verified. No representation or warranty, either express or implied, is made nor responsibility of any kind is accepted by Zeus, its directors or employees either as to the accuracy or completeness of any information stated in this document.

Opinions expressed are the current opinions of Zeus as of the date appearing on this material only. The information and opinions are provided for the benefit of Zeus clients as at the date of this document and are subject to change without notice. Opinions and information disclosed in this publication may have been disclosed to the issuer prior to publication and subsequently amended. There is no regular update series for research issued by Zeus.

The document is not to be construed as a solicitation or recommendation of investment advice and no personal recommendation is being made to you; the securities referred to may not be suitable for you and should not be relied upon in substitution for the exercise of independent judgement. You should make your own investment decisions based upon your own financial objectives and financial resources. Neither past performance nor forecasts are a reliable indication of future performance and Investors may realise losses on any investments, including possible loss of the principal amount invested. Products are not insured by any government or government agencies and are neither guaranteed, insured, nor a deposit account or other obligation of any depository institution.

Zeus and any company or person connected with it (including its officers, directors and employees) may have a position or holding in any investment mentioned in this document or a related investment, and such positions or holdings may be inconsistent with this research recommendation, and may from time to time dispose of any such securities or instrument. In the last 12 months Zeus may have been a manager, or co-lead manager, in the underwriting or placement of securities to the issuers of securities mentioned in this document within the last 12 months, or may have had corporate finance mandates or may have received compensation for investment banking services from such

companies. Zeus, may be, or may have been, party to an agreement with the issuer of the securities mentioned in this document relating to the production of this recommendation. Zeus may receive or may intend to seek compensation for investment banking services from such companies within the next 3 months. A senior executive or director of Zeus or a connected person may be an officer, director or adviser of any issuer of securities mentioned in this document. Accordingly, recipients of this document should not rely on this document being impartial and information may be known to Zeus or persons connected with it which is not reflected in its material.

Zeus has in place a number of mechanisms for identifying and managing potential conflicts which include: Policies and procedures to identify, consider, manage and monitor potential conflicts of interests.

Internal guidance and training regarding the identification of possible conflicts before they arise.

Procedures to ensure that potential conflicts are escalated to the appropriate level within Zeus.

Internal arrangements (including physical separation and other information barriers) for regulating the flow of information between and within business areas.

Zeus shall not be liable for any direct or indirect damages, including lost profits arising in any way from the information contained in this material. This material is for the use of intended recipients only and only for distribution to professional and institutional investors, i.e. persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 of the United Kingdom, or persons who have been categorised as professional customers or eligible counterparties under the rules of FCA. It is not intended for retail customers.

This document is being supplied to you solely for your information and may not be reproduced, re-distributed or passed to any other person or published in whole or in part for any purpose. This material is not directed at you if Zeus is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you and persons into whose possession this material comes should inform themselves about, and observe any such restrictions.

Important Disclosures for United States Persons

Zeus may distribute research, in reliance on Rule 15a-6(a)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), directly to persons in the United States ("U.S.") that are "major US institutional investors" as defined pursuant to Rule 15a-6(b)(4) (each an "MII"). With respect to any distribution of this report to a U.S. person, the information contained in this report (i) is intended solely for use by MII, (ii) was prepared by the analyst named on the cover of this report, who is a non-U.S. research analyst and, as such, may not be subject to all requirements applicable to U.S.-based analysts, (iii) is not subject to all of the independence and disclosure standards applicable to research reports prepared for retail investors, and (iv) may not be used or relied upon by anyone that is not a MII for any purpose. Any U.S. person receiving this report represents and agrees, by virtue of its acceptance thereof, that it is a MII and that it understands the risks involved in executing transactions in such securities.

Any MII that is the recipient of this research and wishes to discuss or receive additional information regarding any security or issuer mentioned herein, or engage in any transaction to purchase or sell or solicit or offer the purchase or sale of such securities, should contact a registered representative of Beech Hill Securities, Inc. (a U.S. broker-dealer registered with the Securities and Exchange Commission and a Member of the Financial Industry Regulatory Authority, Inc.) via telephone at +1 (212) 350-7200 or at its offices at 880 Third Avenue, 16th Floor, New York, NY 10022. Any transaction by such persons (other than a registered U.S. broker-dealer or bank acting in a broker-dealer capacity) must be effected with or through Beech Hill Securities, Inc.

Neither the report nor any analyst who prepared or approved the report is subject to the full scope of U.S. legal or regulatory requirements pertaining to research reports or research analysts. Zeus is neither registered as a broker-dealer under the Exchange Act nor a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization.

To the extent this report relates to non-U.S. securities, note that investing in non-U.S. securities may entail particular risks. Such securities may not be registered under the U.S. Securities Act of 1933, as amended, and the issuer of such

securities may not be subject to U.S. reporting and/or other requirements. Financial statements included in a research report with respect to such securities, if any, may have been prepared in accordance with non-U.S. accounting standards that may not be comparable to the financial statements of U.S. companies. Available information regarding the issuers of such securities may be limited, and such issuers may not be subject to the same auditing and reporting standards as U.S. issuers. Fluctuations in the values of national currencies, as well as the potential for governmental restrictions on currency movements, can significantly erode principal and investment returns. Market rules, conventions and practices may differ from U.S. markets, adding to transaction costs or causing delays in the purchase or sale of such securities. Securities of some non-U.S. companies may not be as liquid as securities of comparable U.S. companies.

The information contained herein may include forward-looking statements within the meaning of U.S. federal securities laws that are subject to risks and uncertainties. Factors that could cause a company's actual results and financial condition to differ from expectations include, without limitation: political uncertainty, changes in general economic conditions that adversely affect the level of demand for the company's products or services, changes in foreign exchange markets, changes in international and domestic financial markets and in the competitive environment, and other factors relating to the foregoing. All forward-looking statements contained in this report are qualified in their entirety by this cautionary statement.

Neither Beech Hill Securities, Inc. nor any affiliate thereof accepts any liability whatsoever for any direct or consequential loss of any kind arising out of the use or reliance on the information given. Research does not take into account the specific investment objectives and financial situation of any recipient, nor does it provide individually tailored investment advice or offer tax, regulatory, accounting or legal advice. Prior to entering into any proposed transaction, recipients should determine, in consultation with their own investment, legal, tax, regulatory and accounting advisors, the economic risks and merits, as well as the legal, tax, regulatory and accounting characteristics and consequences, of any transaction. Investors seeking to buy or sell any financial instruments discussed or recommended in any research report should seek independent financial advice relating thereto.

The products discussed in this report are not FDIC insured, may lose value and are not guaranteed by any Beech Hill Securities, Inc. or Zeus party.

Analyst Certification


Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report.

Additional Disclosures

This material was produced by Zeus solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. This document does not constitute an offer of, or an invitation by or on behalf of Zeus or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which Zeus or its Affiliates consider to be reliable. Zeus does not accept any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. By accepting this document you agree that you have read the above disclaimers, acknowledge them and agree to be bound by all of the foregoing limitations, restrictions and provisions.

1. Zeus or its Affiliates have not recently been the beneficial owners of 1% or more of the securities mentioned in this report.
2. Zeus or its Affiliates have not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
3. Zeus or its Affiliates have received compensation for investment banking services from the issuer of these securities in the past 12 months.
4. However, one or more person of Zeus, or its affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon either on their own account or on behalf of their clients.
5. Zeus, or its affiliates are a market maker in the subject securities.
6. Zeus, or its Affiliates may, to the extent permitted by law, act upon or use the above material or the conclusions stated above or the research or analysis on which they are based before the material is published to recipients and from time to time provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

12 Month Recommendation History



Recommendation distribution at 31 March 2023 Source: Zeus

Corporate Relationships

Nomad & Broker	10
Nomad & Joint Broker	12
Broker	14
Joint Broker	11
Financial Adviser & Broker	2
Research client	8

At 31 March 2023 Source: Zeus

Zeus is a leading independent financial services group working across public and private capital markets in the UK. Our core services include Investment Banking, Equity Sales, Research and Trading, and Investment Management.

We are a highly entrepreneurial firm with a strong track record working with ambitious founders, innovators and their teams to realise the potential of their businesses.

London	125 Old Broad Street London, EC2N 1AR Tel: +44 20 3829 5000
---------------	--

Manchester	82 King Street Manchester, M2 4WQ Tel: +44 161 831 1512
-------------------	--

Birmingham	3 Brindleyplace Birmingham, B1 2JB Tel: +44 121 231 7210
-------------------	---

Edinburgh	15 Queen Street, Edinburgh, EH2 1JE Tel: +44 131 370 3705
------------------	--

info@zeuscapital.co.uk
<https://zeuscapital.co.uk>

zeus
